BioSpace News Archive

Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.

ONK Therapeutics Ltd announced that the European Patent Office has granted its licensed patent covering CISH knockout in NK cells, irrespective of the source of the NK cells, including human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem cells.

Mestag Therapeutics and VIB announced entering into an agreement under which Mestag obtains the exclusive worldwide rights to research, develop and commercialize a panel of single domain antibodies, also known as Nanobodies®, to an undisclosed target that plays a central role in anti-cancer immunity.

Luciole Medical AG, a Swiss medical technology company specialized in brain monitoring, announced the acquisition of Spiegelberg GmbH & Co. KG, an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital.

Allecra Therapeutics announced the submission of a New Drug Application to the U.S. Food and Drug Administration for cefepime/enmetazobactam, an antibiotic combination of the fourth generation cephalosporin cefepime with the proprietary beta lactamase inhibitor, enmetazobactam, for the treatment of complicated urinary tract infections.

Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, announced positive data from a non-human primate study.

Xentria Inc. and Meitheal Pharmaceuticals, Inc. announced an exclusive multi-year licensing agreement to commercialize its lead candidate, and novel biologic, XTMAB-16 for pulmonary sarcoidosis in North America.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that the large multi-center observational registry study INSIGHT has completed enrollment of 5,000 patients with non-small cell lung cancer.

Promore Pharma Promore Pharma AB, reg. no. 556639-6809, held its AGM on Tuesday, 27 June 2023.

Boston Scientific Corporation announced the election of Dr. Jessica L. Mega and Susan E. Morano to its board of directors, each effective immediately.